Acute promyelocytic leukemia medical Interventions: Difference between revisions
No edit summary |
|||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Acute promyelocytic leukemia}} | {{Acute promyelocytic leukemia}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{S.G.}}; {{GRR}} {{Nat}} | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for acute promyelocytic leukemia is [[cytotoxic]] [[chemotherapy]]. Using a combination of all-trans [[retinoic acid]] and [[arsenic trioxide]] is usually reserved for patients with either relapse or resistance to further treatment. | |||
[ | |||
==Indications== | ==Indications== | ||
* patients with | * The mainstay of treatment for acute promyelocytic leukemia is [[cytotoxic]] [[chemotherapy]]. Using a combination of all-trans [[retinoic acid]] and [[arsenic trioxide]] is usually reserved for patients with either relapse or resistance to further treatment.<ref name="pmid27713127">{{cite journal |vauthors=Huang J, Sun M, Wang Z, Zhang Q, Lou J, Cai Y, Chen W, Du X |title=Induction treatments for acute promyelocytic leukemia: a network meta-analysis |journal=Oncotarget |volume=7 |issue=44 |pages=71974–71986 |date=November 2016 |pmid=27713127 |pmc=5342137 |doi=10.18632/oncotarget.12451 |url=}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 13:12, 11 April 2019
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia medical Interventions On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia medical Interventions |
|
Acute promyelocytic leukemia medical Interventions in the news |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia medical Interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]
Overview
The mainstay of treatment for acute promyelocytic leukemia is cytotoxic chemotherapy. Using a combination of all-trans retinoic acid and arsenic trioxide is usually reserved for patients with either relapse or resistance to further treatment.
Indications
- The mainstay of treatment for acute promyelocytic leukemia is cytotoxic chemotherapy. Using a combination of all-trans retinoic acid and arsenic trioxide is usually reserved for patients with either relapse or resistance to further treatment.[1]
References
- ↑ Huang J, Sun M, Wang Z, Zhang Q, Lou J, Cai Y, Chen W, Du X (November 2016). "Induction treatments for acute promyelocytic leukemia: a network meta-analysis". Oncotarget. 7 (44): 71974–71986. doi:10.18632/oncotarget.12451. PMC 5342137. PMID 27713127.